WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck/Schering-Plough Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the inclusion of new data in the product label that showed VYTORIN® (ezetimibe/simvastatin) was more effective than Crestor® (rosuvastatin) at lowering LDL “bad” cholesterol at all doses compared, ranging from the usual recommended starting doses (VYTORIN 10/20 mg, Crestor 10 mg) to the maximum approved doses (VYTORIN 10/80 mg, Crestor 40 mg).
